Literature DB >> 2471563

Anti-alpha-galactosyl antibodies in chagasic patients. Possible biological significance.

S R Milani1, L R Travassos.   

Abstract

1. Antibodies from Chagasic patients (Ch), bound to a column of immobilized purified glycoprotein 25-kDa antigen of Trypanosoma cruzi epimastigotes (gp25), were partially lytic (70% lysis at 50 micrograms/ml) to cultured metacyclic trypomastigotes (Y strain) in a complement-mediated reaction (alternative pathway). 2. Antibodies (Ch) eluted with galactose from a melibiose-Agarose column reacted in ELISA titration plates with gp25, whole cells of metacyclic trypomastigotes (Y strain), and less intensely with aqueous extracts of either T. cruzi (CL-14 strain) or Herpetomonas muscarum. 3. Agglutination of rabbit erythrocytes by anti-Gal antibodies from Chagasic patients or normal human sera (NHS) was inhibited by galactose and alpha-but not beta-anomeric galactosides. 4. Anti-Gal antibodies (Ch or NHS) were lytic to metacyclic trypomastigotes in complement-mediated reactions. 5. Agglutination of rabbit red cells by a serum sample from a T. cruzi-infected Rhesus monkey was inhibited by laminin. This serum was also lytic to metacyclic forms of T. cruzi (Y strain) involving the alternative complement pathway (70% lysis at 1:20 final dilution). 6. These results open the possibility of using anti-Gal antibodies for protection against infection by virulent T. cruzi.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2471563

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  15 in total

1.  Enhancing glycan isomer separations with metal ions and positive and negative polarity ion mobility spectrometry-mass spectrometry analyses.

Authors:  Xueyun Zheng; Xing Zhang; Nathaniel S Schocker; Ryan S Renslow; Daniel J Orton; Jamal Khamsi; Roger A Ashmus; Igor C Almeida; Keqi Tang; Catherine E Costello; Richard D Smith; Katja Michael; Erin S Baker
Journal:  Anal Bioanal Chem       Date:  2016-09-07       Impact factor: 4.142

Review 2.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

3.  Glycoinositol phospholipids from American Leishmania and Trypanosoma spp: partial characterization of the glycan cores and the human humoral immune response to them.

Authors:  J L Avila; M Rojas; A Acosta
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Trypanosoma cruzi cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity.

Authors:  M Pineda; L Corvo; F Callejas-Hernández; M Fresno; P Bonay
Journal:  Clin Exp Immunol       Date:  2019-10-27       Impact factor: 4.330

5.  Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease.

Authors:  Nathaniel S Schocker; Susana Portillo; Carlos R N Brito; Alexandre F Marques; Igor C Almeida; Katja Michael
Journal:  Glycobiology       Date:  2015-09-18       Impact factor: 4.313

6.  Monoclonal antibodies that recognize the trisaccharide epitope Gal alpha 1-3Gal beta 1-4GlcNAc present on Ehrlich tumor cell membrane glycoproteins.

Authors:  M Takagaki; R N Knibbs; J Roth; I J Goldstein
Journal:  Histochemistry       Date:  1993-08

7.  Antibodies to laminin and immunohistochemical localization of laminin in chronic chagasic cardiomyopathy: a review.

Authors:  J Milei; J Sánchez; R Storino; Z X Yu; B Denduchis; V J Ferrans
Journal:  Mol Cell Biochem       Date:  1993-12-22       Impact factor: 3.396

Review 8.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

9.  A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.

Authors:  Maan Zrein; Elodie Granjon; Lucie Gueyffier; Julie Caillaudeau; Peter Liehl; Hans Pottel; Clareci Silva Cardoso; Claudia Di Lorenzo Oliveira; Lea Campos de Oliveira; Tzong-Hae Lee; Ariela Mota Ferreira; Antonio Luiz P Ribeiro; Michael P Busch; Ester Cerdeira Sabino
Journal:  PLoS Negl Trop Dis       Date:  2018-02-09

10.  An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Authors:  Eva Iniguez; Nathaniel S Schocker; Krishanthi Subramaniam; Susana Portillo; Alba L Montoya; Waleed S Al-Salem; Caresse L Torres; Felipe Rodriguez; Otacilio C Moreira; Alvaro Acosta-Serrano; Katja Michael; Igor C Almeida; Rosa A Maldonado
Journal:  PLoS Negl Trop Dis       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.